[A practical strategy for studying hypoglycemia in adults].

P. Guillausseau,J. Lubetzki

DOI: https://doi.org/10.1016/S0248-8663(88)80004-3

1988-11-01

Abstract:

What problem does this paper attempt to address?

Early Decompressing Craniectomy in Patients with Traumatic Brain Injury and Cerebral Edema

Jiang-Biao Gong,Liang Wen,Ren-Ya Zhan,Heng-Jun Zhou,Fang Wang,Gu Li,Xiao-Feng Yang

DOI: https://doi.org/10.5372/1905-7415.0801.261

2014-01-01

Abstract:Background: Decompressing craniectomy (DC) is an important method for the management of severe traumatic brain injury (TBI).Objective: To analyze the effect of prophylactic DC within 24 hours after head trauma TBI.Methods: Seventy-two patients undergoing prophylactic DC for severe TBI were included in this retrospective study. Both of the early and late outcomes were studied and the prognostic factors were analyzed.Results: In this series, cumulative death in the first 30 days after DC was 26%, and 28 (53%) of 53 survivors in the first month had a good outcomes. The factors including Glasgow Coma Score (GCS) score at admission, whether the patient had an abnormal pupil response and whether the midline shift was greater than 5 mm were most important prognostic factors for the prediction of death in the first 30 days and the final outcome at 6 months after DC.Conclusion: Prophylactic DC plays an important role in the management of highly elevated ICP, especially when other methods of reduction of ICP are unavailable.
A Prospective Study of Early Versus Late Craniectomy after Traumatic Brain Injury.

L. Wen,H. Wang,F. Wang,J. B. Gong,G. Li,X. Huang,R. Y. Zhan,X. F. Yang

DOI: https://doi.org/10.3109/02699052.2011.608214

2011-01-01

Brain Injury

Abstract:BACKGROUND:Decompressive craniectomy is an important method for managing traumatic brain injury (TBI). At present, controversies about this procedure exist, especially about the optimum operative time for patients with TBI.METHODS:A prospective study was performed at the First Affiliated Hospital, College of Medicine, Zhejiang University. From January 2008 to December 2009, 25 patients who underwent early decompressive craniectomy were included in the study group, and 19 patients who underwent "late" decompressive craniectomy as a second-tier therapy for intracranial hypertension were included as a comparison group.RESULTS:The 30-day mortality after the operation was 16% in the study group. The overall mortality rate was 20% at the 6-month follow-up. A total of 52% of the patients (13 patients) had good outcomes, and 7 patients remained in a severely disabled or vegetative state. In the comparison group, 4 patients died, and 12 had good outcomes at the 6-month follow-up. The remaining 3 patients had poor outcomes. The study group was well matched with the comparison group. However, the outcomes in the study group were not better than those in the comparison group, as evaluated by the 6-month GOS score.CONCLUSION:Early decompressive craniectomy as a first-tier therapy for intracranial hypertension did not improve patient outcome when compared with "late" decompressive craniectomy for managing TBI.
Outcome of Decompressive Craniectomy for Severe Traumatic Brain Injury Patients with persistently elevated Intracranial Pressure on Medical Treatment. (A Prospective Study Controlled by Intra-parenchymal Pressure Monitoring)

Ahmed Elsayed Saleh,Islam Abou El Fetoh

DOI: https://doi.org/10.21608/bmfj.2022.265462

2022-10-14

Benha Medical Journal

Abstract:Back ground: Traumatic brain injury (TBI) can result in cerebral edema and vascular changes resulting in an increase in intracranial pressure (ICP), which can lead to further secondary damage.Monitoring of ICP is the standard of care for patients with TBI . Objectives: To evaluate outcome of decompressive craniotomy (DC) for management of severe traumatic brain injury (STBI) with persistently elevated intracranial pressure (ICP) on medical treatment and to determine feasibility, safety and accuracy of intraparenchymal ICP monitoring (IPM). Patients and Methods: Forty-one patients admitted to ICU with STBI underwent clinical evaluation. CT scanning was performed for lesions' description and grading with measurement of midline shift (MLS). IPM was inserted and initial ICP was recorded. Patients failed to respond to medical treatment underwent DC. Study outcome included frequency of postoperative (PO) complications and functional outcome judged by Extended Glasgow Outcome Scale (GOSE) 3, 6 and 12-m after hospital discharge. Results: Twenty-seven patients underwent early DC, while 14 patients had late DC. Unilateral craniectomy was performed in 38 patients and bifrontal craniectomy in 3 patients with diffuse cerebral edema and no MLS. During 48-hr PO, arterial pressure measures gradually increased, while ICP gradually decreased and CPP was progressively increased. Mean duration of ICP monitoring was 4±2.4 days, mean duration of ICU stay was 6.8±3.4 days and mean total hospital stay was 11.4±5 days. Five patients developed surgery-related PO complications and 12 patients died, but there was no surgery related mortality. At end of 12-m follow-up; 9 patients had good recovery, 9 patients had moderate disability and 3 had severe disability, while 3 patients were in vegetative state. Conclusion: Short-term trial of medical treatment judged by ICP monitoring of STBI patients allows early surgical decision making. Decompressive craniectomy for patients with persistently elevated ICP provided rapid control of ICP with subsequent improvement of CPP and little PO surgery-related morbidity and no mortality. DC provided acceptable functional outcome with good recovery rate of 37.5%. ICP monitoring using intraparenchymal sensor provided satisfactory perioperative ICP monitoring.
Optimizing Traumatic Brain Injury Recovery: Exploring the Advantages and Results of Decompressive Craniectomy

Aryan Rafieezadeh,Kartik Prabhakaran,Amirhossein Sadeghian,Anna Mary Jose,Bardiya Zangbar

DOI: https://doi.org/10.59556/japi.72.0705

Abstract:Traumatic brain injury (TBI) causes significant mortality and morbidity across regions, imposing a substantial socioeconomic burden on societies. A major complication that can arise is uncontrolled intracranial pressure (ICP). Several strategies exist for reducing ICP in TBI patients, including head elevation, mannitol administration, and hyperventilation. Decompressive craniectomy (DC) is a therapeutic approach employed to lower ICP. This technique offers immediate and permanent relief from elevated ICP, although there are ongoing debates regarding its beneficial use and appropriate indications for patients with increased ICP. The objective of this review was to assess variations in surgical technique, timing of the procedure, and patient characteristics associated with DC. Through the evaluation of clinical and radiologic data concerning DC in patients with elevated ICP, it was revealed that while DC provides numerous benefits, it also carries a significant risk of mortality and morbidity. Furthermore, we observed that factors such as age, initial Glasgow Coma Scale (GCS) score, pupil response, and the time interval between injury and DC can serve as predictors for the procedure's outcomes. Based on our findings, we recommend conducting further trials to shed light on the use of DC in TBI patients.
Intracranial Pressure as an Objective Biomarker of Decompression Adequacy in Large Territory Infarction: A Multicenter Observational Study

Jia Xu Lim,Sherry Jiani Liu,Tien Meng Cheong,Seyed Ehsan Saffari,Julian Xinguang Han,Min Wei Chen

DOI: https://doi.org/10.3389/fsurg.2022.823899

IF: 1.8

2022-05-06

Frontiers in Surgery

Abstract:Background Decompressive craniectomy (DC) improves the survival and functional outcomes in patients with malignant cerebral infarction. Currently, there are no objective intraoperative markers that indicates adequate decompression. We hypothesise that closure intracranial pressure (ICP) correlates with postoperative outcomes. Methods This is a multicentre retrospective review of all 75 DCs performed for malignant cerebral infarction. The patients were divided into inadequate ICP (iICP) and good ICP (gICP) groups based on a suitable ICP threshold determined with tiered receiver operating characteristic and association analysis. Multivariable logistic regression was performed for various postoperative outcomes. Results An ICP threshold of 7 mmHg was determined, with 36 patients (48.0%) and 39 patients (52.0%) in the iICP and gICP group, respectively. After adjustment, postoperative osmotherapy usage was more likely in the iICP group (OR 6.32, p = 0.003), and when given, was given for a longer median duration (iICP, 4 days; gICP, 1 day, p = 0.003). There was no difference in complications amongst both groups. When an ICP threshold of 11 mmHg was applied, there was significant difference in the duration on ventilator (ICP ≥11 mmHg, 3–9 days, ICP <11 mmHg, 3–5 days, p = 0.023). Conclusion Surgical decompression works complementarily with postoperative medical therapy to manage progressive cerebral edema in malignant cerebral infarctions. This is a retrospective study which showed that closure ICP, a novel objective intraoperative biomarker, is able to guide the adequacy of DC in this condition. Various surgical manoeuvres can be performed to ensure that this surgical aim is accomplished.

surgery
Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST-3): a multicentre, randomised, blinded-endpoint, comparative effectiveness study of brain tissue oxygen and intracranial pressure monitoring versus intracranial pressure alone

Francis Bernard,William Barsan,Ramon Diaz-Arrastia,Lisa H Merck,Sharon Yeatts,Lori A Shutter

DOI: https://doi.org/10.1136/bmjopen-2021-060188

IF: 3.006

2022-03-01

BMJ Open

Abstract:Introduction Management of traumatic brain injury (TBI) includes invasive monitoring to prevent secondary brain injuries. Intracranial pressure (ICP) monitor is the main measurement used to that intent but cerebral hypoxia can occur despite normal ICP. This study will assess whether the addition of a brain tissue oxygenation (PbtO 2 ) monitor prevents more secondary injuries that will translate into improved functional outcome. Methods and analysis Multicentre, randomised, blinded-endpoint comparative effectiveness study enrolling 1094 patients with severe TBI monitored with both ICP and PbtO 2 . Patients will be randomised to medical management guided by ICP alone (treating team blinded to PbtO 2 values) or both ICP and PbtO 2 . Management is protocolised according to international guidelines in a tiered approach fashion to maintain ICP 20 mm Hg. ICP and PbtO 2 will be continuously recorded for a minimum of 5 days. The primary outcome measure is the Glasgow Outcome Scale-Extended performed at 180 (±30) days by a blinded central examiner. Favourable outcome is defined according to a sliding dichotomy where the definition of favourable outcome varies according to baseline severity. Severity will be defined according to the probability of poor outcome predicted by the IMPACT core model. A large battery of secondary outcomes including granular neuropsychological and quality of life measures will be performed. Ethics and dissemination This has been approved by Advarra Ethics Committee (Pro00030585). Results will be presented at scientific meetings and published in peer-reviewed publications. Trial registration number ClinicalTrials.gov Registry ( NCT03754114 ).

medicine, general & internal
Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study protocol for a multi-centered two-arm randomized adaptive trial

Jonathan J. Ratcliff,Alex J. Hall,Edoardo Porto,Benjamin R. Saville,Roger J. Lewis,Jason W. Allen,Michael Frankel,David W. Wright,Daniel L. Barrow,Gustavo Pradilla

DOI: https://doi.org/10.3389/fneur.2023.1126958

IF: 3.4

2023-03-17

Frontiers in Neurology

Abstract:Background: Intracerebral hemorrhage (ICH) is a potentially devastating condition with elevated early mortality rates, poor functional outcomes, and high costs of care. Standard of care involves intensive supportive therapy to prevent secondary injury. To date, there is no randomized control study demonstrating benefit of early evacuation of supratentorial ICH. Methods: The Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH) Trial was designed to evaluate the minimally invasive trans-sulcal parafascicular surgery (MIPS) approach, a technique for safe access to deep brain structures and ICH removal using the BrainPath ® and Myriad ® devices (NICO Corporation, Indianapolis, IN). ENRICH is a multi-centered, two-arm, randomized, adaptive comparative-effectiveness study, where patients are block randomized by ICH location and Glasgow Coma Score (GCS) to early ICH evacuation using MIPS plus standard guideline-based management vs. standard management alone to determine if MIPS results in improved outcomes defined by the utility-weighted modified Rankin score (UWmRS) at 180 days as the primary endpoint. Secondary endpoints include clinical and economic outcomes of MIPS using cost per quality-adjusted life years (QALYs). The inclusion and exclusion criteria aim to capture a broad group of patients with high risk of significant morbidity and mortality to determine optimal treatment strategy. Discussion: ENRICH will result in improved understanding of the benefit of MIPS for both lobar and deep ICH affecting the basal ganglia. The ongoing study will lead to Level-I evidence to guide clinicians treatment options in the management of acute treatment of ICH. Trial registration: This study is registered with clinicaltrials.gov (Identifier: NCT02880878).

neurosciences,clinical neurology
Analysis of the efficacy of large decompressive craniectomy in severe traumatic brain injury

LIU Weiguo,FENG Junfeng,YANG Xiaofeng,SHEN Hong,ZHENG Xuesheng,PAN Desheng,YAO Yu,刘伟国,冯军峰,杨小锋,沈宏,郑学胜,潘德生,姚瑜

DOI: https://doi.org/10.3760/j.issn:1671-0282.2005.12.014

IF: 1.473

2005-01-01

Journal of Emergency Medicine

Abstract:Objective To investigate the role of large decompressive craniectomy(LDC) in the management of severe traumatic brain injury(TBI) and very severe TBI,compared with the routine decompressive craniectomy(RDC).Methods Clinical data on 263 patients with severe TBI who were treated by either LDC or RDC in our department were reviewed.One hundred and Thirty-five patients,including 54 very severe TBIs,underwent LDC.Another 128 patients,including 49 very severe TBIs,underwent RDC.Outcomes and postoperative complications of the two kinds of surgical management were compared and analyzed at 6 month follow-up.Results Ninty-six patients(71.7%) obtained effective outcome in the LDC group,while only 75 cases(58.6%) did so in the RDC group.Moreover,the efficacy of LDC to treat very severe TBI was also higher than that of RDC(63.0% vs.36.7%).The incidence of reoperation due to refractory intracranial pressure(ICP) in LDC was significantly lower than that in the RDC group(P<0.05),while the incidence of delayed intracranial hematoma and subdural effusion was significantly higher than that in the RDC group(P<0.05).Conclusion LDC had superiority over RDC in improving the outcome of severe TBI,especially the very severe ones.LDC also could efficiently reduce the chance of reoperation due to refractory ICP,but not the incidence of overall complications.On the contrary,it increased the incidence of delayed intra-cranial hematomas and contralateral subdural effusion.
Primary Decompressive Craniectomy After Traumatic Brain Injury: A Literature Review

Julien N Jost

DOI: https://doi.org/10.7759/cureus.29894

2022-10-04

Cureus

Abstract:Traumatic brain injuries (TBIs) still put a high burden on public health worldwide. Medical and surgical treatment strategies are continuously being studied, but the role and indications of primary decompressive craniectomy (DC) remain controversial. In medically refractory intracranial hypertension after severe traumatic brain injury, secondary decompressive craniectomy is a last resort treatment option to control intracranial pressure (ICP). Randomized controlled studies have been extensively performed on secondary decompressive craniectomy and its role in the management of severe traumatic brain injuries. Indications, prognostic factors, and long-term outcomes in primary decompressive craniectomy during the evacuation of an epidural, subdural, or intracerebral hematoma in the acute phase are still a matter of ongoing research and controversy to this day. Prospective trials have been designed, but the results are yet to be published. In isolated epidural hematoma without underlying brain injury, osteoplastic craniotomy is likely to be sufficient. In acute subdural hematoma (ASDH) with relevant brain swelling and preoperative CT signs such as effaced cisterns, overly proportional midline-shift compared to a relatively small acute subdural hematoma, and accompanying brain contusions as well as pupillary abnormalities, intraventricular hemorrhage, and coagulation disorder, primary decompressive craniectomy is more likely to be of benefit for patients with traumatic brain injury. The role of intracranial pressure monitoring after primary decompressive craniectomy is recommended, but prospective trials are pending. More refined guidelines and hopefully class I evidence will be established with the ongoing trials: randomized evaluation of surgery with craniectomy for patients undergoing evacuation of acute subdural hematoma (RESCUE-ASDH), prospective randomized evaluation of decompressive ipsilateral craniectomy for traumatic acute epidural hematoma (PREDICT-AEDH), and pragmatic explanatory continuum indicator summary (PRECIS).
Decompressive craniectomy: A primer for acute care practitioners

Peter George Brindley,Mark Sanderson,Dustin Anderson,Cian O'Kelly

DOI: https://doi.org/10.1177/17511437241237760

2024-03-24

Abstract:Decompressive craniectomy (DC) involves surgical removal of the skull that overlies swollen, imperiled, brain. This is done to combat intracranial hypertension and mitigate a vicious cycle of secondary brain injury. If, instead, this pathophysiology goes uninterrupted, it can mean brain herniation and brain stem death. As such, DC can save lives when all else fails. Regardless, it is no panacea and can also "ruin deaths," and leave patients profoundly disabled. DC is not a new procedure; however, this therapy is increasingly noteworthy due to advances in neurocritical care, alongside ethical concerns. We cover the physiological rationale, the surgical basics, the trial data, and focus on secondary decompression (for refractory intracranial pressure (ICP)) rather than primary decompression (i.e. during evacuation of an intracranial mass). Given that DC should not be undertaken indiscriminately, we conclude by introducing ways in which to discuss DC with families and colleagues. Our goal is to provide a primer and common resource for the multidisciplinary team. We aim to increase not only knowledge but wisdom, prudence, collegiality, and family-focused care.
Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial

David Cederberg,Bradley M. Harrington,Adriaan Johannes Vlok,Peter Siesjö

DOI: https://doi.org/10.1186/s13063-022-06275-z

IF: 2.728

2022-04-24

Trials

Abstract:Background Traumatic brain injury (TBI) constitutes a global epidemic. Overall outcome is poor, with mortality ranging from 10 to 70% and significant long-term morbidity. Several experimental reports have claimed effect on traumatic edema, but no clinical trials have shown effect on edema or outcome. Antisecretory factor, an endogenous protein, is commercially available as Salovum®, which is classified as a medical food by the European Union and has shown effect in experimental trauma models and feasibility with signs of effect in 2 pilot case series. The aim of this study is to assess the effect of antisecretory factor in adult patients with severe traumatic brain injury as measured by 30-day mortality, treatment intensity level (TIL), and intracranial pressure (ICP). Methods/design This is a single-center, double-blind, randomized, placebo-controlled clinical phase 2 trial, investigating the clinical superiority of Salovum® given as a food supplement to adults with severe TBI (GCS < 9), presenting to the trauma unit at Tygerberg University Hospital, Cape Town, South Africa, that are planned for invasive ICP monitoring and neurointensive care, will be screened for eligibility, and assigned to either treatment group ( n = 50) or placebo group ( n = 50). In both groups, the primary outcome will be 30-day mortality, recorded via hospital charts, follow-up phone calls, and the population registry. Secondary outcomes will be treatment intensity level (TIL), scored from hospital charts, and ICP registered from hospital data monitoring. Trial registration ClinicalTrials.gov NCT03339505. Registered on September 17, 2017. Protocol version 3.0 from November 13, 2020

medicine, research & experimental
A trial of intracranial pressure monitoring in traumatic brain injury

Samer Melhem,Lori Shutter,A Kaynar

DOI: https://doi.org/10.1186/cc13713

IF: 15.1

2014-01-01

Critical Care

Abstract:BACKGROUND: Intracranial pressure (ICP) monitoring is considered the standard of care for severe traumatic brain injury (TBI) and is used frequently, but the efficacy of treatment based on monitoring in improving the outcome has not been rigorously assessed.METHODS: OBJECTIVE: The objective was to compare efficacy of guideline-based management in which a protocol for monitoring intraparenchymal ICP was used (ICP group) or a protocol in which treatment was based on imaging and clinical examination (exam group).DESIGN: A multicenter randomized controlled trial was conducted.SETTING: The trial was set in ICUs in Bolivia or Ecuador.SUBJECTS: Patients had severe TBI (n = 324) and were 13 years of age or older.INTERVENTIONS: Patients were randomly allocated to ICP monitoring or clinical exam-based monitoring.OUTCOMES: The primary outcome was a composite of survival time, impaired consciousness, functional status at 3 and 6 months, and neuropsychological status at 6 months; neuropsychological status was assessed by an examiner who was unaware of the protocol assignment. This composite measure was based on performance across 21 measures of functional and cognitive status and was calculated as a percentile (with 0 indicating the worst performance, and 100 the best performance).RESULTS: There was no significant between-group difference in the primary outcome, a composite measure based on percentile performance across 21 measures of functional and cognitive status (score 56 in the pressure-monitoring group versus 53 in the imaging-clinical examination group; P = 0.49). Six-month mortality rates were 39% in the pressure-monitoring group and 41% in the imaging-clinical examination group (P = 0.60). The median lengths of stay in the ICU were similar in the two groups (12 days in the pressure-monitoring group and 9 days in the imaging-clinical examination group; P = 0.25), although the number of days of brain-specific treatments (for example, administration of hyperosmolar fluids and the use of hyperventilation) in the ICU was higher in the imaging-clinical examination group than in the pressure-monitoring group (4.8 versus 3.4, P = 0.002). The distributions of serious adverse events were similar in the two groups.CONCLUSIONS: For patients with severe TBI, care focused on maintaining monitored ICP at 20 mmHg or less was not shown to be superior to care based on imaging and clinical examination.

critical care medicine
Simulations of clonal species genotypic diversity – trembling aspen (Populus tremuloïdes) as a case study

Marie-Claire Namroud,Alain Leduc,F. Tremblay,Y. Bergeron

DOI: https://doi.org/10.1007/s10592-005-9051-3

2006-04-11

Conservation Genetics

Abstract:
Clot removAl with or without decompRessive craniectomy under ICP monitoring for supratentorial IntraCerebral Hemorrhage (CARICH): a randomized controlled trial

Chao Zhang,Shuixian Zhang,Yi Yin,Long Wang,Lan Li,Chuan Lan,Jiantao Shi,Zhouyang Jiang,Hongfei Ge,Xuegang Li,Zaiyong Ao,Shengli Hu,Jingyu Chen,Hua Feng,Rong Hu

DOI: https://doi.org/10.1097/js9.0000000000001466

2024-04-19

International Journal of Surgery

Abstract:Background: Decompressive craniectomy, a surgery to remove part of the skull and open the dura mater, maybe an effective treatment for controlling intracranial hypertension. It remains great interest to elucidate whether decompressive craniectomy is beneficial to intracerebral hemorrhage patients who warrant clot removal to prevent intracranial hypertension. Methods: The trial was a prospective, pragmatic, controlled trial involving adult patients with intracerebral hemorrhage who were undergoing removal of hematoma. Intracerebral hemorrhage patients were randomly assigned at a 1:1 ratioto undergo clot removal with or without decompressive craniectomy under the monitoring of intracranial pressure. The primary outcome was the proportion of unfavorable functional outcome (modified Rankin Scale 3-6) at 3 months. Secondary outcomes included the mortality at 3 months and the occurrence of re-operation. Results: A total of 102 patients were assigned to the clot removal with decompressive craniectomy group and 102 to the clot removal group. Median hematoma volume was 54.0 mL (range 30-80 mL) and median preoperative Glasgow Coma Scale was 10 (range 5-15). At 3 months, 94 patients (92.2%) in clot removal with decompressive craniectomy group and 83 patients (81.4%) in the clot removal group had unfavorable functional outcome ( P =0.023). Fourteen patients (13.7%) in the clot removal with decompressive craniectomy group died versus five patients (4.9%) in the clot removal group ( P =0.030). The number of patients with re-operation was similar between the clot removal with decompressive craniectomy group and clot removal group (5.9% vs. 3.9%; P =0.517). Postoperative intracranial pressure values were not significantly different between two groups and the mean values were less than 20 mmHg. Conclusions: Clot removal without decompressive craniectomy decreased the rate of modified Rankin Scale score of 3-6 and mortality in patients with intracerebral hemorrhage, compared with clot removal with decompressive craniectomy.

surgery
High K+ and IGF‐1 protect cerebellar granule neurons via distinct signaling pathways

J. Zhong,Jixian Deng,Su Huang,Xianlin Yang,Wei-Hua Lee

DOI: https://doi.org/10.1002/jnr.20024

IF: 4.433

2004-03-15

Journal of Neuroscience Research

Abstract:In culture, cerebellar granule neurons die of apoptosis in serum‐free media containing a physiologic level of K+ but survive in a depolarizing concentration of K+ or when insulin‐like growth factor 1 (IGF‐1) is added. Both Akt/PKB activation and caspase‐3 inhibition were implicated as the underlying neuroprotective mechanisms. The duration of high K+, however, induced survival effects that outlasted its transient activation of Akt, and granule neurons derived from caspase‐3 knockout mice died to the same extent as did those from wild‐type mice, suggesting that additional mechanisms are involved. To delineate these survival mechanisms, we compared the activities of two major survival pathways after high K+‐induced depolarization or IGF‐1 stimulation. Although IGF‐1 promoted neuronal survival by activating its tyrosine kinase receptor, high K+ depolarization provided the same effect by increasing the Ca2+ influx through the L Ca2+ channel. Moreover, high K+‐induced depolarization resulted in sustained activation of MAP kinase, whereas IGF‐1 activated Akt in 4 hr. Inhibition of MEK (MAP kinase kinase) by either PD98059 or UO126 abolished the protective effect of high K+‐induced depolarization, but not that of IGF‐1, suggesting that activation of the MAP kinase pathway is necessary for high K+ neuroprotective effects. We demonstrated also that high K+‐induced depolarization, but not IGF‐1, increased phosphorylation of cAMP‐response element‐binding protein (CREB) and protein synthesis, both of which can be blocked by UO126. Overall, our findings suggested that high K+‐induced depolarization, unlike IGF‐1, promoted neuronal survival via activating MAP kinase, possibly by increasing CREB‐dependent transcriptional activation of specific proteins that promote neuronal survival. © 2004 Wiley‐Liss, Inc.
Surgical trial in traumatic intracerebral hemorrhage (STITCH(Trauma)): study protocol for a randomized controlled trial

Barbara A Gregson,Elise N Rowan,Patrick M Mitchell,Andy Unterberg,Elaine M McColl,Iain R Chambers,Paul McNamee,A David Mendelow

DOI: https://doi.org/10.1186/1745-6215-13-193

IF: 2.728

2012-10-16

Trials

Abstract:Abstract Background Intracranial hemorrhage occurs in over 60% of severe head injuries in one of three types: extradural (EDH); subdural (SDH); and intraparenchymal (TICH). Prompt surgical removal of significant SDH and EDH is established and widely accepted. However, TICH is more common and is found in more than 40% of severe head injuries. It is associated with a worse outcome but the role for surgical removal remains undefined. Surgical practice in the treatment of TICHs differs widely around the world. The aim of early surgery in TICH removal is to prevent secondary brain injury. There have been trials of surgery for spontaneous ICH (including the STICH II trial), but none so far of surgery for TICH. Methods/Design The UK National Institutes of Health Research has funded STITCH(Trauma) to determine whether a policy of early surgery in patients with TICH improves outcome compared to a policy of initial conservative treatment. It will include a health economics component and carry out a subgroup analysis of patients undergoing invasive monitoring. This is an international multicenter pragmatic randomized controlled trial. Patients are eligible if: they are within 48 h of injury; they have evidence of TICH on CT scan with a confluent volume of attenuation significantly raised above that of the background white and grey matter that has a total volume >10 mL; and their treating neurosurgeon is in equipoise. Patients will be ineligible if they have: a significant surface hematoma (EDH or SDH) requiring surgery; a hemorrhage/contusion located in the cerebellum; three or more separate hematomas fulfilling inclusion criteria; or severe pre-existing physical or mental disability or severe co-morbidity which would lead to poor outcome even if the patient made a full recovery from the head injury. Patients will be randomized via an independent service. Patients randomized to surgery receive surgery within 12 h. Both groups will be monitored according to standard neurosurgical practice. All patients have a CT scan at 5 days (+/−2 days) to assess changes in hematoma size. Follow-up is by postal questionnaire at 6 and 12 months. The recruitment target is 840 patients. Trial registration Current Controlled Trials ISRCTN19321911

medicine, research & experimental
Early mobilisation by head-up tilt with stepping versus standard care after severe traumatic brain injury – Protocol for a randomised clinical feasibility trial

Christian Gunge Riberholt,Jane Lindschou,Christian Gluud,Jesper Mehlsen,Kirsten Møller

DOI: https://doi.org/10.1186/s13063-018-3004-x

IF: 2.728

2018-11-08

Trials

Abstract:BackgroundIntensive rehabilitation of patients with severe traumatic brain injury is generally applied in the subacute stages of the hospital stay. Few studies have assessed the association between early and intensive physical rehabilitation and functional outcomes. The aim of this trial is to assess the feasibility of an intensive physical rehabilitation intervention focusing on mobilisation to the upright position, starting as early as clinically possible versus standard care in the intensive care unit. The feasibility study is intended to inform a subsequent randomised clinical trial that will investigate benefits and harms of the intervention.MethodsThis randomised clinical feasibility trial with a follow-up period of 1 year will use blinded outcome assessors for the Coma Recovery Scale–Revised. A maximum of 60 patients admitted to the neurointensive care unit at Rigshospitalet, Denmark, with traumatic brain injury (age of at least 18 years), a low level of consciousness, and stable intracranial pressure will be included in the trial. Patients will be randomly assigned to experimental intervention versus standard care (1:1) stratified according to their Glasgow Coma Score. The intervention group will receive daily mobilisation in a tilt table with an integrated stepping device (ERIGO®). Feasibility is declared if more than 60% (the lower 95% confidence interval of the proportion) of eligible patients are included in the trial and more than 52% (the lower 95% confidence interval of the proportion) of patients in the intervention group receive more than 60% of the planned interventions. Safety is assessed by the occurrence of adverse events and adverse reactions. Exploratory clinical outcomes consist of cerebral haemodynamics (blood flow velocity and pressure autoregulation) and baroreceptor sensitivity in the early phase as well as functional outcomes (Coma Recovery Scale–Revised, Early Functional Ability scale, and Functional Independence Measure).DiscussionOur findings will inform a future, larger-scale randomised clinical trial on early mobilisation using a tilt table early after severe traumatic brain injury.Trial registrationClinicalTrials.gov identifier: NCT02924649. Registered on 3 October 2016.

medicine, research & experimental
PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in Australia

Toby Jeffcote,Camila R Battistuzzo,Mark P Plummer,Robert McNamara,James Anstey,Judith Bellapart,Rebecca Roach,Andrew Chow,Torgeir Westerlund,Anthony Delaney,Shailesh Bihari,David Bowen,Mark Weeden,Anthony Trapani,Michael Reade,Rosalind L Jeffree,Melinda Fitzgerald,Belinda J Gabbe,Terence J O'Brien,Alistair D Nichol,D James Cooper,Rinaldo Bellomo,Andrew Udy,Jeffcote,T.,Battistuzzo,C. R.,Plummer,M. P.,McNamara,R.,Anstey,J.,Bellapart,J.,Roach,R.,Chow,A.,Westerlund,T.,Delaney,A.,Bihari,S.,Bowen,D.,Weeden,M.,Trapani,A.,Reade,M.,Jeffree,R. L.,Fitzgerald,M.,Gabbe,B. J.,O'Brien,T. J.,Nichol,A. D.,Cooper,D. J.,Bellomo,R.,Udy,A.

DOI: https://doi.org/10.1136/bmjopen-2023-080614

IF: 3.006

2024-02-22

BMJ Open

Abstract:Introduction Traumatic brain injury (TBI) is a heterogeneous condition in terms of pathophysiology and clinical course. Outcomes from moderate to severe TBI (msTBI) remain poor despite concerted research efforts. The heterogeneity of clinical management represents a barrier to progress in this area. PRECISION-TBI is a prospective, observational, cohort study that will establish a clinical research network across major neurotrauma centres in Australia. This network will enable the ongoing collection of injury and clinical management data from patients with msTBI, to quantify variations in processes of care between sites. It will also pilot high-frequency data collection and analysis techniques, novel clinical interventions, and comparative effectiveness methodology. Methods and analysis PRECISION-TBI will initially enrol 300 patients with msTBI with Glasgow Coma Scale (GCS) <13 requiring intensive care unit (ICU) admission for invasive neuromonitoring from 10 Australian neurotrauma centres. Demographic data and process of care data (eg, prehospital, emergency and surgical intervention variables) will be collected. Clinical data will include prehospital and emergency department vital signs, and ICU physiological variables in the form of high frequency neuromonitoring data. ICU treatment data will also be collected for specific aspects of msTBI care. Six-month extended Glasgow Outcome Scores (GOSE) will be collected as the key outcome. Statistical analysis will focus on measures of between and within-site variation. Reports documenting performance on selected key quality indicators will be provided to participating sites. Ethics and dissemination Ethics approval has been obtained from The Alfred Human Research Ethics Committee (Alfred Health, Melbourne, Australia). All eligible participants will be included in the study under a waiver of consent (hospital data collection) and opt-out (6 months follow-up). Brochures explaining the rationale of the study will be provided to all participants and/or an appropriate medical treatment decision-maker, who can act on the patient's behalf if they lack capacity. Study findings will be disseminated by peer-review publications. Trial registration number NCT05855252.

medicine, general & internal
Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial

Jürgen Beck,Christian Fung,Daniel Strbian,Lukas Bütikofer,Werner J Z'Graggen,Matthias F Lang,Seraina Beyeler,Jan Gralla,Florian Ringel,Karl Schaller,Nikolaus Plesnila,Marcel Arnold,Werner Hacke,Peter Jüni,Alexander David Mendelow,Christian Stapf,Rustam Al-Shahi Salman,Jenny Bressan,Stefanie Lerch,Arsany Hakim,Nicolas Martinez-Majander,Anna Piippo-Karjalainen,Peter Vajkoczy,Stefan Wolf,Gerrit A Schubert,Anke Höllig,Michael Veldeman,Roland Roelz,Andreas Gruber,Philip Rauch,Dorothee Mielke,Veit Rohde,Thomas Kerz,Eberhard Uhl,Enea Thanasi,Hagen B Huttner,Bernd Kallmünzer,L Jaap Kappelle,Wolfgang Deinsberger,Christian Roth,Robin Lemmens,Jan Leppert,Jose L Sanmillan,Jonathan M Coutinho,Katharina A M Hackenberg,Gernot Reimann,Mikael Mazighi,Claudio L A Bassetti,Heinrich P Mattle,Andreas Raabe,Urs Fischer,SWITCH study investigators,Lukas Andereggen,Kerim Beseoglu,Carlo Cereda,Daniel Coluccia,Philippe Desfontaines,Maria Alonso de Leciñana,Christian Freyschlag,Thomas Gaberel,Rüdiger Gerlach,Florian Gessler,Erdem Güresir,Fernando Muñoz,Ramazan Jabbarli,Jens Minnerup,Francisco Moniche,Andre Peeters,Waltraud Pfeilschifter,Turgut Tatlisumak,Judith Weiland,Johannes Woitzik,Maria Wostrack,W P Vandertop

DOI: https://doi.org/10.1016/S0140-6736(24)00702-5

2024-06-01

Abstract:Background: It is unknown whether decompressive craniectomy improves clinical outcome for people with spontaneous severe deep intracerebral haemorrhage. The SWITCH trial aimed to assess whether decompressive craniectomy plus best medical treatment in these patients improves outcome at 6 months compared to best medical treatment alone. Methods: In this multicentre, randomised, open-label, assessor-blinded trial conducted in 42 stroke centres in Austria, Belgium, Finland, France, Germany, the Netherlands, Spain, Sweden, and Switzerland, adults (18-75 years) with a severe intracerebral haemorrhage involving the basal ganglia or thalamus were randomly assigned to receive either decompressive craniectomy plus best medical treatment or best medical treatment alone. The primary outcome was a score of 5-6 on the modified Rankin Scale (mRS) at 180 days, analysed in the intention-to-treat population. This trial is registered with ClincalTrials.gov, NCT02258919, and is completed. Findings: SWITCH had to be stopped early due to lack of funding. Between Oct 6, 2014, and April 4, 2023, 201 individuals were randomly assigned and 197 gave delayed informed consent (96 decompressive craniectomy plus best medical treatment, 101 best medical treatment). 63 (32%) were women and 134 (68%) men, the median age was 61 years (IQR 51-68), and the median haematoma volume 57 mL (IQR 44-74). 42 (44%) of 95 participants assigned to decompressive craniectomy plus best medical treatment and 55 (58%) assigned to best medical treatment alone had an mRS of 5-6 at 180 days (adjusted risk ratio [aRR] 0·77, 95% CI 0·59 to 1·01, adjusted risk difference [aRD] -13%, 95% CI -26 to 0, p=0·057). In the per-protocol analysis, 36 (47%) of 77 participants in the decompressive craniectomy plus best medical treatment group and 44 (60%) of 73 in the best medical treatment alone group had an mRS of 5-6 (aRR 0·76, 95% CI 0·58 to 1·00, aRD -15%, 95% CI -28 to 0). Severe adverse events occurred in 42 (41%) of 103 participants receiving decompressive craniectomy plus best medical treatment and 41 (44%) of 94 receiving best medical treatment. Interpretation: SWITCH provides weak evidence that decompressive craniectomy plus best medical treatment might be superior to best medical treatment alone in people with severe deep intracerebral haemorrhage. The results do not apply to intracerebral haemorrhage in other locations, and survival is associated with severe disability in both groups. Funding: Swiss National Science Foundation, Swiss Heart Foundation, Inselspital Stiftung, and Boehringer Ingelheim.
Effects of transcranial direct current stimulation on patients with disorders of consciousness after traumatic brain injury: study protocol for a randomized, double-blind controlled trial

Shilin Li,Xiangli Dong,Weiming Sun,Na Zhao,Guohua Yu,Lang Shuai

DOI: https://doi.org/10.1186/s13063-019-3680-1

IF: 2.728

2019-10-17

Trials

Abstract:Background: Disorders of consciousness (DOC) after traumatic brain injury (TBI) raise the mortality of patients, restrict the rehabilitation of patients with TBI, and increase the physical and economic burden that TBI imposes on patients and their families. Thus, treatment to promote early awakening in DOC after TBI is of vital importance. Various treatments have been reported, but there is no advanced evidence base to support them. Transcranial direct current stimulation (tDCS) has shown great potential in promoting neuroelectrochemical effects. This protocol is for a double-blind, randomized, controlled, clinical trial aiming to research the effects and safety of conventional rehabilitation combined with tDCS therapy in patients with DOC after TBI. Methods/design: Eighty patients with DOC after TBI will be randomized into one of two groups receiving conventional rehabilitation combined with sham tDCS or conventional rehabilitation combined with active tDCS. The intervention period in each of the two groups will last 4 weeks (20 min per day, 6 days per week). Primary outcomes (Glasgow Outcome Scale (GOS)) will be measured at baseline and the end of every week from the first to the fourth week. Secondary outcomes will be measured at baseline and the end of the fourth week. Adverse events and untoward effects will be measured during each treatment. Discussion: Patients with central nervous system lesions have received tDCS as a painless, non-invasive, easily applied and effective therapy for several decades, and there has been some evidence in recent years showing partial improvement on the level of consciousness of partial patients with DOC. However, reports mainly focus on the patients in a minimally conscious state (MCS), and there is a lack of large-sample clinical trials. This protocol presents an objective design for a randomized controlled trial that aims to study the effectiveness of conventional rehabilitation combined with tDCS therapy for DOC after TBI, to evaluate its safety, and to explore effective and economical therapeutic methods. Trial registration: Chinese Clinical Trial Registry, ChiCTR1800014808 . Registered on 7 February 2018.

[A practical strategy for studying hypoglycemia in adults].

Early Decompressing Craniectomy in Patients with Traumatic Brain Injury and Cerebral Edema

A Prospective Study of Early Versus Late Craniectomy after Traumatic Brain Injury.

Outcome of Decompressive Craniectomy for Severe Traumatic Brain Injury Patients with persistently elevated Intracranial Pressure on Medical Treatment. (A Prospective Study Controlled by Intra-parenchymal Pressure Monitoring)

Optimizing Traumatic Brain Injury Recovery: Exploring the Advantages and Results of Decompressive Craniectomy

Intracranial Pressure as an Objective Biomarker of Decompression Adequacy in Large Territory Infarction: A Multicenter Observational Study

Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST-3): a multicentre, randomised, blinded-endpoint, comparative effectiveness study of brain tissue oxygen and intracranial pressure monitoring versus intracranial pressure alone

Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): Study protocol for a multi-centered two-arm randomized adaptive trial

Analysis of the efficacy of large decompressive craniectomy in severe traumatic brain injury

Primary Decompressive Craniectomy After Traumatic Brain Injury: A Literature Review

Decompressive craniectomy: A primer for acute care practitioners

Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial

A trial of intracranial pressure monitoring in traumatic brain injury

Simulations of clonal species genotypic diversity – trembling aspen (Populus tremuloïdes) as a case study

Clot removAl with or without decompRessive craniectomy under ICP monitoring for supratentorial IntraCerebral Hemorrhage (CARICH): a randomized controlled trial

High K+ and IGF‐1 protect cerebellar granule neurons via distinct signaling pathways

Surgical trial in traumatic intracerebral hemorrhage (STITCH(Trauma)): study protocol for a randomized controlled trial

Early mobilisation by head-up tilt with stepping versus standard care after severe traumatic brain injury – Protocol for a randomised clinical feasibility trial

PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in Australia

Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial

Effects of transcranial direct current stimulation on patients with disorders of consciousness after traumatic brain injury: study protocol for a randomized, double-blind controlled trial